🇺🇸 FDA

Intelligence Platform

Patents

Browse 912 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10883994

Identification of cancer stem cells markers and use of same for diagnosis and treatment

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10881689

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10874631

Altertoxin II as a selective inhibitor of Ewing family of tumor cells

The Board of Regents of the University of Texas System · Granted Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10865387

Methods of obtaining pancreatic endocrine cells

THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN REGENT WALK · Granted Tue Dec 15 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857185

Compositions and methods for reprogramming non-neuronal cells into neuron-like cells

BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10857184

Materials and methods for engineering cells and uses thereof in immuno-oncology

CRISPR THERAPEUTICS AG · Granted Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10849912

Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10842823

Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progeni

United Therapeutics Corporation · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10842826

Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses ther

UNIVERSITY OF CONNECTICUT · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10844353

Methods for preparing therapeutically active cells using microfluidics

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Nov 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10821134

BK virus specific T cells

The Board of Regents of the University of Texas System · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10821178

Methods of treating biofilm infections comprising administering inhibitors of myeloid-deri

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10821078

Nanostructure enhanced targeting (NSET) of inflammatory cells

Northwestern University · Granted Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10813952

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 27 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10808225

Use of PDL1 expressing cells to convert T cells into regulatory T cells

The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10808230

Selection methods for genetically-modified T cells

The Board of Regents of the University of Texas System · Granted Tue Oct 20 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10800833

Co-stimulatory domains for use in genetically-modified cells

Precision BioSciences, Inc. · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10799584

Combination therapies using agents that target tumor-associated stroma or tumor cells and

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10799461

Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially

EnGeneIC Molecular Delivery Pty Ltd · Granted Tue Oct 13 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10765727

Compositions and methods for producing dendritic cells

PrimeVax Immuno-Oncology · Granted Tue Sep 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758613

Combination therapies using anti-metabolites and agents that target tumor-associated strom

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10759863

Modulation of γδ T cells

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10760048

In vitro production of medial ganglionic eminence precursor cells

The Regents of the University of California · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10758614

Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, OFFICE OF TECHNOLOGY TRANSFER—NATIONAL INSTITUTES OF HEALTH · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted